Chemed (FRA:CXM) Total Equity: €734 Mil (As of Mar. 2026)


FRA:CXM Chemed Corp FRA:CXM
78 GF Score
Price €394.00
GF Value €562.39
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Chemed Total Equity?

Chemed FRA:CXM +1.03% 78 Total Equity is €734 Mil as of Mar. 2026. GuruFocus rates FRA:CXM with a GF Score™ of 78/100 and a GF Value™ of €562.39 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Chemed's total equity for the quarter that ended in Mar. 2026 was €734 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Chemed Total Equity Historical Data

* Premium members only.

The historical data trend for Chemed's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemed Total Equity Chart

Chemed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 551.60 753.99 1,015.92 1,068.64 836.41

Chemed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,093.13 1,039.09 917.33 836.41 733.52
FRA:CXM
78GF Score
Chemed Corp FRA:CXM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemed Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Chemed's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1313.613-477.202
=836

Chemed's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1328.48-594.965
=734

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €734 Mil mean?
Chemed (FRA:CXM) has a Total Equity of €734 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Chemed and its competitors.
Is Chemed's Total Equity too high?
Chemed's current Total Equity is €734 Mil. Overall, Chemed has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Total Equity compare to PACS and LFST?
Chemed's Total Equity of €734 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Chemed and its competitors. Chemed's current Total Equity is €734 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €562.39, compared to a current price of €394.00 — trading 29.9% below its estimated fair value. The current Total Equity is €734 Mil. Chemed's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Total Equity is €734 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemed (FRA:CXM) Overvalued in 2026?

Based on GuruFocus' analysis, Chemed stock appears to be undervalued. The current stock price of €394.00 is trading 29.9% below its estimated GF Value™ of €562.39. GuruFocus considers Chemed to be Significantly Undervalued.

Key valuation signals for FRA:CXM:

  • Total Equity: €734 Mil
  • GF Value™: €562.39 vs. price of €394.00 (29.9% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chemed Business Description

Other Exchanges CHE:USA
Address 255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
78GF Score

Get the complete analysis for FRA:CXM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€394.00
Price
€562.39
GF Value